Remove 2016 Remove Competition Remove Doctors Remove Physicians
article thumbnail

Comparison of Humira biosimilars in the US and Europe

Pharmaceutical Technology

Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. However, it has taken over six years for Amjevita to launch, after first being FDA-approved in 2016. Many other biosimilars have also been FDA-approved since 2016.

article thumbnail

The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!

PharmaKinnex

The pharmaceutical industry of 2022 is very different from the space that we all knew in 2012, 2016, or even 2020. Let’s dive into the current state of the pharma industry and learn more about what your team can do to stay ahead of the curve and the competition. The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!

Pharma 52
article thumbnail

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

pharmaphorum

The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face. However, most doctors polled by IQVIA consistently state that whilst they are happy to manage many aspects of patient care remotely where possible, they want to see the patient face-to-face to prescribe a newly launched medicine.

Doctors 57